Who are GBP510 adjuvanted with AS03's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Recombinant influenza hemagglutinin, FluBlok, Meningococcal B (Bexsero), Licensed 4CMenB vaccine, Novavax recombinant protein vaccine, Licensed seasonal influenza vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gbp510-adjuvanted-with-as03.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

GBP510 adjuvanted with AS03 — Competitive Intelligence Brief

GBP510 adjuvanted with AS03 (GBP510 adjuvanted with AS03) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant protein vaccine. Area: Immunology / Infectious Disease.

phase 3 Recombinant protein vaccine Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

GBP510 adjuvanted with AS03 (GBP510 adjuvanted with AS03) — SK Bioscience Co., Ltd.. GBP510 is a recombinant protein subunit vaccine designed to stimulate immune responses against a specific pathogen or disease target, formulated with AS03 adjuvant to enhance immunogenicity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
GBP510 adjuvanted with AS03 TARGET	GBP510 adjuvanted with AS03	SK Bioscience Co., Ltd.	phase 3	Recombinant protein vaccine
Recombinant influenza hemagglutinin	Recombinant influenza hemagglutinin	Vaxine Pty Ltd	marketed	Recombinant protein vaccine	Influenza hemagglutinin
FluBlok	FluBlok	The University of Hong Kong	marketed	Recombinant protein vaccine	Influenza hemagglutinin (HA)
Meningococcal B (Bexsero)	Meningococcal B (Bexsero)	University of Sao Paulo General Hospital	marketed	Recombinant protein vaccine	Meningococcal serogroup B surface antigens (recombinant Neisseria meningitidis proteins)
Licensed 4CMenB vaccine	Licensed 4CMenB vaccine	University of Adelaide	marketed	Recombinant protein vaccine	Neisseria meningitidis serogroup B surface antigens
Novavax recombinant protein vaccine	Novavax recombinant protein vaccine	Henry M. Jackson Foundation for the Advancement of Military Medicine	marketed	Recombinant protein vaccine	Viral surface antigens (e.g., SARS-CoV-2 spike protein)
Licensed seasonal influenza vaccine	Licensed seasonal influenza vaccine	Novavax	marketed	Recombinant protein vaccine with adjuvant	Influenza hemagglutinin (HA) protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant protein vaccine class)

GlaxoSmithKline · 6 drugs in this class
Novavax · 5 drugs in this class
Vaxine Pty Ltd · 2 drugs in this class
D'Or Institute for Research and Education · 2 drugs in this class
Protein Sciences Corporation · 2 drugs in this class
Henogen · 1 drug in this class
Henry M. Jackson Foundation for the Advancement of Military Medicine · 1 drug in this class
Institut National de la Santé Et de la Recherche Médicale, France · 1 drug in this class
National Vaccine and Serum Institute, China · 1 drug in this class
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GBP510 adjuvanted with AS03 — Competitive Intelligence Brief. https://druglandscape.com/ci/gbp510-adjuvanted-with-as03. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab